From the Academic Unit of Ophthalmology (Tomlins, Rauz) and School of Immunity and Infection (Murray), University of Birmingham, Good Hope Hospital (Sivaraj), and Queen Elizabeth Hospital Birmingham (Denniston), University Hospitals NHS Foundation Trust, Birmingham, United Kingdom.
From the Academic Unit of Ophthalmology (Tomlins, Rauz) and School of Immunity and Infection (Murray), University of Birmingham, Good Hope Hospital (Sivaraj), and Queen Elizabeth Hospital Birmingham (Denniston), University Hospitals NHS Foundation Trust, Birmingham, United Kingdom.
J Cataract Refract Surg. 2014 Apr;40(4):618-25. doi: 10.1016/j.jcrs.2013.09.013. Epub 2014 Feb 26.
To report the long-term visual outcomes and biocompatibility of a single-piece hydrophilic acrylic intraocular lens (IOL) in patients with uveitis having cataract surgery.
Tertiary referral center, Birmingham, United Kingdom.
Retrospective case review.
The review included consecutive uveitis patients in whom phacoemulsification and acrylic IOL implantation was performed by the same surgeon. Outcomes measures are reported as rate/eye-year and included visual acuity and signs of bioincompatibility.
The review identified 171 eyes (140 patients; mean age 51 years [range 16 to 85 years]) with uveitis. The mean follow-up was 3.8 years (range 0.9 to 10.3 years). Signs of uveal bioincompatibility were found in 31 eyes, with visually insignificant deposits on the IOL in 17 eyes. The rate of uveal bioincompatibility was 0.06/eye-year. Signs of capsule bioincompatibility were found in 107 (63%) of 171 eyes (0.31/eye-year). Posterior capsule opacification was documented in 102 eyes (0.29/eye-year); neodymium:YAG laser capsulotomy was required in 31 eyes (0.05/eye-year). The rate of failure to maintain a 3 logMAR line improvement in corrected distance visual acuity (CDVA) was 0.08/eye-year; to maintain better than 0.3 logMAR, 0.15/eye-year; and to maintain either, 0.04/eye-year. At 1 year, 85% of eyes had a CDVA of better than 0.3 logMAR or maintained a 3 logMAR-line improvement. Eyes with preexisting macular or optic nerve disease had significantly worse visual outcomes.
The long-term safety profile of the hydrophilic acrylic IOL was good in uveitis cases, leading to good visual outcomes and a low rate of vision-impairing uveal and capsule complications.
No author has a financial or proprietary interest in any material or method mentioned.
报告在患有葡萄膜炎并接受白内障手术的患者中，使用亲水丙烯酸一体式人工晶状体（IOL）的长期视力结果和生物相容性。
英国伯明翰的三级转诊中心。
回顾性病例研究。
该研究纳入了由同一位外科医生进行白内障超声乳化吸除术和丙烯酸 IOL 植入术的连续葡萄膜炎患者。视力结果以每眼年的发生率进行报告，包括视力和生物不相容的迹象。
研究共纳入了 171 只眼（140 例患者；平均年龄 51 岁[16 至 85 岁]）的葡萄膜炎病例。平均随访时间为 3.8 年（0.9 至 10.3 年）。31 只眼出现葡萄膜生物不相容的迹象，其中 17 只眼的 IOL 上有轻微的不可见沉积物。葡萄膜生物不相容的发生率为 0.06 每眼年。171 只眼中有 107 只眼（63%）出现囊膜生物不相容的迹象（0.31 每眼年）。102 只眼（29%）记录到后囊膜混浊；31 只眼（0.05 每眼年）需要行钕：钇铝石榴石激光后囊膜切开术。无法保持矫正远视力（CDVA）提高 3 个 logMAR 线的失败率为 0.08 每眼年；保持优于 0.3 logMAR 的比例为 0.15 每眼年；保持其中任何一个的比例为 0.04 每眼年。术后 1 年，85%的眼 CDVA 优于 0.3 logMAR 或保持 3 logMAR 线的提高。有黄斑或视神经疾病的眼视力结果明显较差。
亲水丙烯酸 IOL 在葡萄膜炎病例中具有良好的长期安全性，可获得良好的视力结果，并降低视力受损的葡萄膜和囊膜并发症的发生率。
无作者在文中提到的任何材料或方法上存在经济或所有权利益。
